X4 Pharmaceuticals, Inc.
NASDAQ:XFOR · NASDAQ Capital Market
+$0.12 today
Vol 0.46M · Avg 0.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.5%
avg -12.1%
ROIC
-32.7%
avg -460.5%
ROA
-27.3%
avg -105.3%
Analysis
ROA is currently the strongest return metric at -27.3% versus its period average of -105.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David H. Kirske | Chief Financial Officer, Treasurer & Corporate Secretary | $722,331.00 | — | 72 | $176,293.00 | 0.19% |
Adam R. Craig | Executive Chair | $575,546.00 | — | 60 | $2.33M | 2.47% |
John Volpone | President & Chief Operating Officer | $532,988.00 | — | 51 | $2.33M | 2.47% |
Keith T. Flaherty | Founder & Member of Corporate Advisory Board | — | — | 55 | $6,000.00 | <0.01% |
Richard Peters | Founder | — | — | 64 | — | — |
Renato T. Skerlj | Founder | — | — | — | $42,076.00 | 0.04% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$249,997.40
Sells
1
$72,820.36
Net Sentiment
+$177,177.04
Net buying
Most Active
KIRSKE DAVID
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 12, 2026 | KIRSKE DAVID Direct | Sell | 17.0K | $4.29 | $72,820.36 | |
| Oct 23, 2025 | Craig Adam R Direct | Buy | 86.2K | $2.90 | $249,997.40 |
Analysis
Insiders reported 1 buys worth $249,997.40 and 1 sells worth $72,820.36 over the last 12 months. That adds up to net buying of $177,177.04. KIRSKE DAVID was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$215.30M
Mersana Therapeutics, Inc.
MRSN
$145.36M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$57.43M
Kezar Life Sciences, Inc.
KZR
$53.86M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$32.97M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Skye Bioscience, Inc.
SKYE
$27.67M
Senti Biosciences, Inc.
SNTI
$25.24M
Tempest Therapeutics, Inc.
TPST
$5.60M
Who manages XFOR?
X4 Pharmaceuticals, Inc. (XFOR) lists 6 active executives. The top listed executive is Keith T. Flaherty, Founder & Member of Corporate Advisory Board.
Are XFOR insiders buying or selling?
Recent insider activity shows net buying of $24.65M.
Explore More
Continue the stock analysis
Jump to another research area for this company.